Consolidated Statement Of Profit Or Loss

Astellas Pharma Inc. - Filing #7258550

Concept 2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
Consolidated statement of profit or loss
Statement of profit or loss
Revenue
1,912,323,000,000 JPY
1,603,672,000,000 JPY
Cost of sales
349,206,000,000 JPY
292,485,000,000 JPY
Gross profit
1,563,117,000,000 JPY
1,311,187,000,000 JPY
Selling, general and administrative expenses
843,032,000,000 JPY
740,110,000,000 JPY
Other income
20,344,000,000 JPY
8,691,000,000 JPY
Other expenses
235,768,000,000 JPY
167,814,000,000 JPY
Operating profit (loss)
41,039,000,000 JPY
25,518,000,000 JPY
Finance income
7,874,000,000 JPY
11,455,000,000 JPY
Finance costs
17,677,000,000 JPY
12,005,000,000 JPY
Share of profit (loss) of investments accounted for using equity method
-259,000,000 JPY
-3,165,000,000 JPY
Profit (loss) before tax
31,237,000,000 JPY
24,969,000,000 JPY
Income tax expense
-19,510,000,000 JPY
7,924,000,000 JPY
Profit (loss)
50,747,000,000 JPY
JPY
JPY
50,747,000,000 JPY
JPY
50,747,000,000 JPY
JPY
JPY
JPY
JPY
JPY
JPY
JPY
JPY
17,045,000,000 JPY
JPY
JPY
JPY
JPY
JPY
JPY
JPY
17,045,000,000 JPY
17,045,000,000 JPY
JPY
JPY
Profit (loss) attributable to
Owners of parent
50,747,000,000 JPY
17,045,000,000 JPY
Earnings (loss) per share
Basic earnings (loss) per share
28.35
9.51
Diluted earnings (loss) per share
28.24
9.47

Talk to a Data Expert

Have a question? We'll get back to you promptly.